Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.51.3
PrivacidadTérminosCookiesAviso Legal
● Connected
RTGN US Equity
RetinalGenix Technologies Inc.
3.99USD
Healthcare
Medical Devices
96)Comparar97)Tesis →
Market Cap
$75M
Shares Outstanding
19M
Net Income (TTM)
−$2M
— Annual —FY2025
Current Ratio
0.01
Book Value / Share
-0.12
RTGN US Equity
3.99USD
Tesis →

RetinalGenix Technologies Inc. (RTGN): análisis fundamental y valoración

RetinalGenix Technologies Inc. cotiza a 3.99 USD y tiene una capitalización bursátil de $75M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaOTCPaísUnited StatesBeta-3.30Web↗ retinalgenix.com

RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide fie…

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
—
P/Book
—
Rentabilidad (Último Anual)
Gross Margin
—
Operating Margin
—
Net Margin
—
FCF Margin
—
ROE
—
ROCE
—
ROA
-11542.2%
Effective Tax Rate
—
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
—
Net Income TTM
−$2M
FCF TTM
—
EPS TTM
-0.12
Quarters Used
4
TTM Period
2025-09-30 → 2026-06-30
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
0.01
Interest Coverage
—
Working Capital
−$2M
Book Value / Share
-0.12
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
—
Net Income YoY
+43.8%
FCF YoY
—
EPS Diluted YoY
+45.8%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
—
CapEx % Revenue
—
Rev / Employee
—
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaRTGNMediana SectorΔ
Gross Margin—57.0%—
Operating Margin—-38.6%—
Net Margin—-33.6%—
FCF Margin—-13.9%—
ROE—-40.4%—
ROA-11542.2%-32.0%-11510.2%
Current Ratio0.012.84-2.83
Debt / Equity—0.28—
Scoring Fundamental
Capital Allocation
0/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✗DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✗Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)